**DRAFT Medical Coverage Policy** | Percutaneous Electrical Nerve Stimulation, Percutaneous Neuromodulation Therapy, and Restorative Neurostimulation Therapy



**EFFECTIVE DATE:** 02|01|2024 **POLICY LAST REVIEWED:** 10|04|2023

#### **OVERVIEW**

Percutaneous electrical nerve stimulation (PENS), percutaneous neuromodulation therapy (PNT), and restorative neurostimulation therapy (ReActiv8) combine the features of electroacupuncture and transcutaneous electrical nerve stimulation. Percutaneous electrical nerve stimulation is performed with needle electrodes while PNT uses very fine needle-like electrode arrays placed near the painful area to stimulate peripheral sensory nerves in the soft tissue. ReActiv8 is an implantable electrical neurostimulation system that stimulates the nerves that innervate the lumbar multifidus muscles.

#### **MEDICAL CRITERIA**

Not applicable

#### **PRIOR AUTHORIZATION**

Not applicable

# POLICY STATEMENT

# Medicare Advantage Plans

Restorative neurostimulation therapy (ReActiv8), Percutaneous electrical neurostimulation (PENS) or percutaneous neuromodulation therapy (PNT) for the treatment of chronic pain conditions is considered medically necessary if pain is effectively controlled by percutaneous stimulation and implantation of electrodes is warranted.

**Note:** Blue Cross & Blue Shield of Rhode Island (BCBSRI) must follow Centers for Medicare and Medicaid Services (CMS) guidelines, such as national coverage determinations or local coverage determinations for all Medicare Advantage Plans policies. Therefore, Medicare Advantage Plans policies may differ from Commercial products. In some instances, benefits for Medicare Advantage Plans may be greater than what is allowed by the CMS.

#### **Commercial Products**

Restorative neurostimulation therapy (ReActiv8), Percutaneous electrical neurostimulation (PENS) or percutaneous neuromodulation therapy (PNT) for the treatment of chronic pain conditions is considered not medically necessary as the evidence is insufficient to determine the effects of the technology on health outcomes.

#### **COVERAGE**

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable surgery or not medically necessary benefits/coverage.

### BACKGROUND

A variety of chronic musculoskeletal or neuropathic pain conditions, including low back pain, neck pain, diabetic neuropathy, chronic headache, and surface hyperalgesia, present a substantial burden to patients, adversely affecting function and quality of life. Certain racial and ethnic groups are at a higher risk of developing diabetes, which may also put them at higher risk of developing complications from diabetes, such as diabetic neuropathy. According to a 2018 to 2019 National Health Interview Survey and data from the

Indian Health Service National Data Warehouse, American Indians and Alaska Natives had the highest reported rate of diagnosed diabetes at 14.5%. This was followed by 12.1% of Black individuals, 11.8% of Hispanic individuals, 9.5% of Asian individuals, and 7.4% of White individuals having diagnosed diabetes in 2018 or 2019.

These chronic pain conditions have typically failed other treatments, and percutaneous electrical nerve stimulation (PENS) and percutaneous neuromodulation therapy (PNT) have been evaluated as treatments to relieve unremitting pain.

Percutaneous electrical nerve stimulation is similar in concept to transcutaneous electrical nerve stimulation (TENS) (see evidence review 1.01.09) but differs in that needles are inserted either around or immediately adjacent to the nerves serving the painful area and are then stimulated. Percutaneous electrical nerve stimulation is generally reserved for patients who fail to get pain relief from TENS. Percutaneous electrical nerve stimulation is also distinguished from acupuncture with electrical stimulation. In electrical acupuncture, needles are also inserted just below the skin, but the placement of needles is based on specific theories regarding energy flow throughout the human body. In PENS, the location of stimulation is determined by proximity to the pain.

Percutaneous neuromodulation therapy is a variant of PENS in which fine filament electrode arrays are placed near the area causing pain. Some use the terms PENS and PNT interchangeably. It is proposed that PNT inhibits pain transmission by creating an electrical field that hyperpolarizes C fibers, thus preventing action potential propagation along the pain pathway.

The purpose of restorative neurostimulation therapy in individuals with chronic pain conditions is to provide a treatment option that is an alternative to or an improvement on existing therapies. The ReActiv8 System is an implantable electrical neurostimulation system that stimulates the nerves that innervate the lumbar multifidus muscles.

## Medicare Advantage Plans

PENS, which involves stimulation of peripheral nerves by a needle electrode inserted through the skin is performed only in a physician's office, clinic, or hospital outpatient department. Therefore, it is covered only when performed by a physician or incident to physician's service. If pain is effectively controlled by percutaneous stimulation, implantation of electrodes is warranted.

## **Commercial Products**

For individuals who have chronic pain conditions (e.g., back, neck, neuropathy, headache, hyperalgesia) who receive PENS, the evidence includes primarily small controlled trials and 2 systematic reviews. Relevant outcomes are symptoms, functional outcomes, quality of life, and medication use. Two systematic reviews have not revealed consistent benefit from PENS in musculoskeletal pain disorders. One review concluded that PENS could decrease pain intensity but not related disability, while the other found no significant differences between PENS and TENS in mitigation of pain. These conclusions are uncertain due to important methodological limitations in individual trials included in these reviews, such as high heterogeneity with regard to application methods. In the highest quality trial of PENS conducted to date in chronic low back pain, no difference in outcomes was found between the active (30 minutes of stimulation with 10 needles) and the sham (5 minutes of stimulation with 2 needles) treatments. Smaller trials, which have reported positive results, are limited by unclear blinding and short-term follow-up. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have chronic pain conditions (eg, knee osteoarthritis) who receive PNT, the evidence consists of a randomized controlled trial (RCT). Relevant outcomes are symptoms, functional outcomes, quality of life, and medication use. The single trial is limited by lack of investigator blinding, unclear

participant blinding, and short-term follow-up. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have chronic pain conditions including low back pain who receive restorative neurostimulation therapy (ReActiv8), the evidence includes 1 sham-controlled RCT (N = 204), 1 prospective single-arm trial (N = 53), and a case series (N = 44). Relevant outcomes are symptoms, functional outcomes, quality of life, and medication use. In the RCT, there was no difference between groups on the primary endpoint of treatment response at 120 days, defined as the composite of 30% or greater reduction in VAS and no increase in pain medications (57.1% intervention vs 46.6% sham; p =.1377). Prespecified secondary analyses of primary outcome data favored the intervention group, but clinical significance is unclear. An uncontrolled follow-up phase of the RCT reported continued improvement in pain scores through 3 years but results are at high risk of bias due to lack of a control group and high attrition. Nonrandomized studies are limited by lack of blinding, no sham control, high attrition. and small sample sizes. Additional evidence from longer-term sham-controlled RCTs is needed. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

## CODING

### Medicare Advantage Plans and Commercial Products

There is not a specific code for PENS or PNT. Use the unlisted code below **64999** Unlisted procedure, nervous system

### **RELATED POLICIES**

Lysis of Epidural Adhesions Nerve Graft with Radical Prostatectomy Occipital Nerve Stimulation – Insertion Peripheral Subcutaneous Field Stimulation Pulsed Radiofrequency for the Treatment of Chronic Pain Sphenopalatine Ganglion Block for Headache Unlisted Procedures

#### PUBLISHED

Provider Update, February 2024 Provider Update, December 2023 Provider Update, October 2022 Provider Update, October 2021 Provider Update, September 2020

### REFERENCES

Centers for Disease Control and Prevention (CDC). By the Numbers: Diabetes in America. UpdatedMarch 2022; https://www.cdc.gov/diabetes/health-equity/diabetes-by-the-numbers.html. Accessed June26, 2023.
 Food & Drug Administration. 2020. ReActiv8 Implantable Neurostimulation System. Approval Order.https://www.accessdata.fda.gov/cdrh\_docs/pdf19/P190021A.pdf. Accessed June 25, 2023.
 Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACTrecommendations. Pain. Jan 2005; 113(1-2): 9-19. PMID 15621359
 Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes inchronic pain clinical trials: IMMPACT recommendations. J Pain. Feb 2008; 9(2): 105-21. PMID18055266
 Gewandter JS, Dworkin RH, Turk DC, et al. Research design considerations for chronic pain preventionclinical trials: IMMPACT recommendations. Pain. Jul 2015; 156(7): 1184-1197. PMID 25887465
 Plaza-Manzano G, Gómez-Chiguano GF, Cleland JA, et al. Effectiveness of percutaneous electricalnerve stimulation for musculoskeletal pain: A systematic review and meta-analysis. Eur J Pain. Jul 2020;24(6): 1023-1044. PMID 32171035

7. Beltran-Alacreu H, Serrano-Muñoz D, Martín-Caro Álvarez D, et al. Percutaneous VersusTranscutaneous Electrical Nerve Stimulation for the Treatment of Musculoskeletal Pain. A SystematicReview and Meta-Analysis. Pain Med. Aug 01 2022; 23(8): 1387-1400. PMID 35167691

8. Ghoname EA, Craig WF, White PF, et al. Percutaneous electrical nerve stimulation for low back pain: arandomized crossover study. JAMA. Mar 03 1999; 281(9): 818-23. PMID 10071003

9. Ghoname ES, Craig WF, White PF, et al. The effect of stimulus frequency on the analgesic response topercutaneous electrical nerve stimulation in patients with chronic low back pain. Anesth Analg. Apr1999; 88(4): 841-6. PMID 10195535

10. Hamza MA, Ghoname EA, White PF, et al. Effect of the duration of electrical stimulation on theanalgesic response in patients with low back pain. Anesthesiology. Dec 1999; 91(6): 1622-7. PMID1059860224. Medeiros LF, Caumo W, Dussán-Sarria J, et al. Effect of Deep Intramuscular Stimulation and Transcranial Magnetic Stimulation on Neurophysiological Biomarkers in Chronic Myofascial PainSyndrome. Pain Med. Jan 2016; 17(1): 122-35. PMID 26408420

11.Weiner DK, Rudy TE, Glick RM, et al. Efficacy of percutaneous electrical nerve stimulation for thetreatment of chronic low back pain in older adults. J Am Geriatr Soc. May 2003; 51(5): 599-608. PMID12752833

12. Topuz O, Ozfidan E, Ozgen M, Ardic F. Efficacy of transcutaneous electrical nerve stimulation and percutaneous neuromodulation therapy in chronic low back pain. J Back Musculoskeletal Rehabil.2004;17:127-133.

13.Yokoyama M, Sun X, Oku S, et al. Comparison of percutaneous electrical nerve stimulation with transcutaneous electrical nerve stimulation for long-term pain relief in patients with chronic low backpain. Anesth Analg. Jun 2004; 98(6): 1552-1556. PMID 15155304

14.Weiner DK, Perera S, Rudy TE, et al. Efficacy of percutaneous electrical nerve stimulation and therapeutic exercise for older adults with chronic low back pain: a randomized controlled trial. Pain. Nov30 2008; 140(2): 344-357. PMID 18930352

15.Perez-Palomares S, Olivan-Blazquez B, Magallon-Botaya, et al. Percutaneous electrical nervestimulation versus dry needling: effectiveness in the treatment of chronic low back pain. JMusculokeletal Pain. 2010;18:23-30.

16.Weiner DK, Rudy TE, Morone N, et al. Efficacy of periosteal stimulation therapy for the treatment ofosteoarthritis-associated chronic knee pain: an initial controlled clinical trial. J Am Geriatr Soc. Oct 2007;55(10): 1541-7. PMID 17908057

17.Weiner DK, Moore CG, Morone NE, et al. Efficacy of periosteal stimulation for chronic pain associated with advanced knee osteoarthritis: a randomized, controlled clinical trial. Clin Ther. Nov 2013; 35(11):1703-20.e5. PMID 24184053

18.da Graca-Tarragó M, Deitos A, Patrícia Brietzke A, et al. Electrical Intramuscular Stimulation inOsteoarthritis Enhances the Inhibitory Systems in Pain Processing at Cortical and Cortical SpinalSystem. Pain Med. May 01 2016; 17(5): 877-891. PMID 26398594

19.Elbadawy MA. Effectiveness of Periosteal Stimulation Therapy and Home Exercise Program in theRehabilitation of Patients With Advanced Knee Osteoarthritis. Clin J Pain. Mar 2017; 33(3): 254-263.PMID 27513639

20.Dunning J, Butts R, Henry N, et al. Electrical dry needling as an adjunct to exercise, manual therapyand ultrasound for plantar fasciitis: A multi-center randomized clinical trial. PLoS One. 2018; 13(10):e0205405. PMID 30379937

21.da Graca-Tarragó M, Lech M, Angoleri LDM, et al. Intramuscular electrical stimulus potentiates motorcortex modulation effects on pain and descending inhibitory systems in knee osteoarthritis: arandomized, factorial, sham-controlled study. J Pain Res. 2019; 12: 209-221. PMID 30655690 22.León-Hernández JV, Martín-Pintado-Zugasti A, Frutos LG, et al. Immediate and short-term effects of

the combination of dry needling and percutaneous TENS on post-needling soreness in patients with chronicmyofascial neck pain. Braz J Phys Ther. Jul 11 2016; 20(5): 422-431. PMID 27410163 23.Sumen A, Sarsan A, Alkan H, et al. Efficacy of low level laser therapy and intramuscular electrical stimulation on myofascial pain syndrome. J Back Musculoskelet Rehabil. 2015; 28(1): 153-8. PMID25061034 24. Medeiros LF, Caumo W, Dussán-Sarria J, et al. Effect of Deep Intramuscular Stimulation and Transcranial Magnetic Stimulation on Neurophysiological Biomarkers in Chronic Myofascial PainSyndrome. Pain Med. Jan 2016; 17(1): 122-35. PMID 26408420

25. Botelho L, Angoleri L, Zortea M, et al. Insights About the Neuroplasticity State on the Effect ofIntramuscular Electrical Stimulation in Pain and Disability Associated With Chronic Myofascial PainSyndrome (MPS): A Double-Blind, Randomized, Sham-Controlled Trial. Front Hum Neurosci. 2018; 12:388. PMID 30459575

26. Dunning J, Butts R, Young I, et al. Periosteal Electrical Dry Needling as an Adjunct to Exercise andManual Therapy for Knee Osteoarthritis: A Multicenter Randomized Clinical Trial. Clin J Pain. Dec 2018;34(12): 1149-1158. PMID 29864043

27. Yoshimizu M, Teo AR, Ando M, Kiyohara K, Kawamura T. Relief of chronic shoulder and neck pain byelectro-acupuncture and transcutaneous electrical nervous stimulation: A randomized crossover trial.Med Acupunct 2012;24(2):97103.

28. Ng MM, Leung MC, Poon DM. The effects of electro-acupuncture and transcutaneous electrical nervestimulation on patients with painful osteoarthritic knees: a randomized controlled trial with follow-upevaluation. J Altern Complement Med. Oct 2003; 9(5): 641-9. PMID 14629842

29. Tsukayama H, Yamashita H, Amagai H, et al. Randomised controlled trial comparing the effectivenessof electroacupuncture and TENS for low back pain: a preliminary study for a pragmatic trial. AcupunctMed. Dec 2002; 20(4): 175-80. PMID 12512791

30. Cheng RSS, Pomeranz B. Electrotheraphy of chronic musculoskeletal pain: Comparison ofelectroacupuncture and acupuncture-like transcutaneous electrical nerve stimulation. Cochrane Library.Clin J Pain 1986;2(3):1439.

31. Lehmann TR, Russell DW, Spratt KF, et al. Efficacy of electroacupuncture and TENS in therehabilitation of chronic low back pain patients. Pain. Sep 1986; 26(3): 277-290. PMID 2946016

32. Ghoname EA, White PF, Ahmed HE, et al. Percutaneous electrical nerve stimulation: an alternative to TENS in the management of sciatica. Pain. Nov 1999; 83(2): 193-9. PMID 10534590

33. White PF, Craig WF, Vakharia AS, et al. Percutaneous neuromodulation therapy: does the location ofelectrical stimulation effect the acute analgesic response? Anesth Analg. Oct 2000; 91(4): 949-54.PMID 11004055

34. Hamza MA, White PF, Craig WF, et al. Percutaneous electrical nerve stimulation: a novel analgesictherapy for diabetic neuropathic pain. Diabetes Care. Mar 2000; 23(3): 365-70. PMID 10868867

35. Ahmed HE, White PF, Craig WF, et al. Use of percutaneous electrical nerve stimulation (PENS) in theshort-term management of headache. Headache. Apr 2000; 40(4): 311-5. PMID 10759936

36. Raphael JH, Raheem TA, Southall JL, et al. Randomized double-blind sham-controlled crossover studyof short-term effect of percutaneous electrical nerve stimulation in neuropathic pain. Pain Med. Oct2011; 12(10): 1515-22. PMID 21883874

37. Kang RW, Lewis PB, Kramer A, et al. Prospective randomized single-blinded controlled clinical trial ofpercutaneous neuromodulation pain therapy device versus sham for the osteoarthritic knee: a pilotstudy. Orthopedics. Jun 2007; 30(6): 439-45. PMID 17598487

38. Gilligan C, Volschenk W, Russo M, et al. An implantable restorative-neurostimulator for refractorymechanical chronic low back pain: a randomized sham-controlled clinical trial. Pain. Oct 01 2021;162(10): 2486-2498. PMID 34534176

39. Food & Drug Administration. 2020. ReActiv8 Implantable Neurostimulation System: Summary of Safetyand Effectiveness Data. https://www.accessdata.fda.gov/cdrh\_docs/pdf19/P190021B.pdf. AccessedJune 23, 2023.

40. Gilligan C, Volschenk W, Russo M, et al. Long-Term Outcomes of Restorative Neurostimulation inPatients With Refractory Chronic Low Back Pain Secondary to Multifidus Dysfunction: Two-Year Resultsof the ReActiv8-B Pivotal Trial. Neuromodulation. Jan 2023; 26(1): 87-97. PMID 35088722 41. Gilligan C, Volschenk W, Russo M, et al. Three-Year Durability of Restorative

NeurostimulationEffectiveness in Patients With Chronic Low Back Pain and Multifidus Muscle Dysfunction.Neuromodulation. Jan 2023; 26(1): 98-108. PMID 36175320

42. Deckers K, De Smedt K, Mitchell B, et al. New Therapy for Refractory Chronic Mechanical Low BackPain-Restorative Neurostimulation to Activate the Lumbar Multifidus: One Year Results of a ProspectiveMulticenter Clinical Trial. Neuromodulation. Jan 2018; 21(1): 48-55. PMID 29244235
43. Thomson S, Chawla R, Love-Jones S, et al. Restorative Neurostimulation for Chronic Mechanical LowBack Pain: Results from a Prospective Multi-centre Longitudinal Cohort. Pain Ther. Dec 2021; 10(2):1451-1465. PMID 34478115

44. Mitchell B, Deckers K, De Smedt K, et al. Durability of the Therapeutic Effect of RestorativeNeurostimulation for Refractory Chronic Low Back Pain. Neuromodulation. Aug 2021; 24(6): 1024-1032.PMID 34242440

45. Ardeshiri A, Shaffrey C, Stein KP, et al. Real-World Evidence for Restorative Neurostimulation inChronic Low Back Pain-a Consecutive Cohort Study. World Neurosurg. Dec 2022; 168: e253-e259.PMID 36184040 46. Bril V, England J, Franklin GM, et al. Evidence-based guideline: Treatment of painful diabeticneuropathy: report of the American Academy of Neurology, the American Association of Neuromuscularand Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation.Neurology. May 17 2011; 76(20): 1758-65. PMID 21482920

47. Price R, Smith D, Franklin G, et al. Oral and Topical Treatment of Painful Diabetic Polyneuropathy:Practice Guideline Update Summary: Report of the AAN Guideline Subcommittee. Neurology. Jan 042022; 98(1): 31-43. PMID 34965987

48. Chou R, Qaseem A, Snow V, et al. Diagnosis and treatment of low back pain: a joint clinical practiceguideline from the American College of Physicians and the American Pain Society. Ann Intern Med. Oct02 2007; 147(7): 478-91. PMID 17909209

49. Qaseem A, Wilt TJ, McLean RM, et al. Noninvasive Treatments for Acute, Subacute, and Chronic LowBack Pain: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. Apr04 2017; 166(7): 514-530. PMID 28192789

50. Benzon HT, Connis RT, De Leon-Casasola OA, et al. Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic PainManagement and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology. Apr2010; 112(4): 810-33. PMID 20124882

51. National Institute for Health and Care Excellence (NICE). Percutaneous electrical nerve stimulation forrefractory neuropathic pain [IPG450]. 2013; https://www.nice.org.uk/guidance/ipg450. Accessed June25, 2023.

52. National Institute for Health and Care Excellence. 2022 Neurostimulation of lumbar muscles forrefractory nonspecific chronic low back pain: Interventional Procedures

Guidance.https://www.nice.org.uk/guidance/ipg739. Accessed June 26, 2023.

53. Centers for Medicare & Medicaid. National Coverage Determination (NCD) for Assessing

Patient'sSuitability for ELECTRICAL NERVE STIMULATION Therapy (160.7.1).

2006;https://www.cms.gov/medicare-coverage- database/details/ncd-

details.aspx?NCDId=63&ncdver=2&CoverageSelection=National&KeyWord=Electrical+Nerve+Stimulatio n&KeyWordLookUp=Title&KeyWordSearchType=And&list\_type=ncd&bc=gAAAABAAAAA&. Accessed June6, 2023.

#### CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

